VAXART INC. - COMMON STOCK

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

11 3 2025 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

05 3 2025 15:05:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

24 2 2025 08:51:01 提供 NetDania Notify

Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

28 1 2025 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

14 1 2025 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

13 1 2025 18:55:00 提供 Nasdaq GlobeNewswire

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

02 12 2024 15:01:00 提供 Nasdaq GlobeNewswire

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

13 11 2024 15:01:00 提供 Nasdaq GlobeNewswire

Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13

07 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024

24 10 2024 07:00:01 提供 Nasdaq GlobeNewswire

Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need

15 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

30 9 2024 15:12:22 提供 Nasdaq GlobeNewswire

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia

28 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

08 8 2024 15:01:00 提供 Nasdaq GlobeNewswire

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

02 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Provides Business Update

17 6 2024 15:05:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

17 6 2024 14:51:57 提供 NetDania Notify

Vaxart Announces $40 Million Underwritten Offering of Common Stock

13 6 2024 18:07:26 提供 Nasdaq GlobeNewswire